| LncTarD: A manually-curated database of experimentally-supported functional lncRNA–target regulations in human diseases H Zhao, J Shi, Y Zhang, A Xie, L Yu, C Zhang, J Lei, H Xu, Z Leng, T Li, ... Nucleic acids research 48 (D1), D118-D126, 2020 | 102 | 2020 |
| Comprehensive landscape of epigenetic-dysregulated lncRNAs reveals a profound role of enhancers in carcinogenesis in BC subtypes H Zhao, X Liu, L Yu, S Lin, C Zhang, H Xu, Z Leng, W Huang, J Lei, T Li, ... Molecular Therapy-Nucleic Acids 23, 667-681, 2021 | 53 | 2021 |
| LncTarD 2.0: an updated comprehensive database for experimentally-supported functional lncRNA–target regulations in human diseases H Zhao, X Yin, H Xu, K Liu, W Liu, L Wang, C Zhang, L Bo, X Lan, S Lin, ... Nucleic Acids Research 51 (D1), D199-D207, 2023 | 17 | 2023 |
| Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer L Wang, L Yu, J Shi, F Li, C Zhang, H Xu, X Yin, L Wang, S Lin, ... Scientific reports 12 (1), 10641, 2022 | 11 | 2022 |
| The dynamic dysregulated network identifies stage-specific markers during lung adenocarcinoma malignant progression and metastasis L Wang, W Liu, K Liu, L Wang, X Yin, L Bo, H Xu, S Lin, K Feng, X Zhou, ... Molecular Therapy-Nucleic Acids 30, 633-647, 2022 | 2 | 2022 |
| Identifying enhancer-driven subtype-specific prognostic markers in breast cancer based on multi-omics data H Zhao, S Zhang, X Yin, C Zhang, L Wang, K Liu, H Xu, W Liu, L Bo, S Lin, ... Frontiers in Immunology 13, 990143, 2022 | 2 | 2022 |
| Systematic identification of drug-based prognostic biomarkersby integrating multiomics in breast cancer H Zhao, L Yu, Y Ping, S Lin, C Zhang, H Xu, T Li, W Huang, J Lei, Z Leng, ... | | 2020 |
